[1]郭召平,苏琴,黄天生.化痰助运通络方治疗痰瘀互结型非酒精性脂肪肝肝纤维化临床研究[J].西部中医药,2021,34(05):122-126.[doi:10.12174/j.issn.2096-9600.2021.05.31]
　GUO Zhaoping,SU Qin,HUANG Tiansheng.Clinical Study on Treating Non Alcoholic Fatty Liver Fibrosis of Phlegm and Blood Stasis Pattern by Resolving-phlegm Promoting-transportation Dredging-collateral Prescription[J].Western Journal of Traditional Chinese Medicine,2021,34(05):122-126.[doi:10.12174/j.issn.2096-9600.2021.05.31]
点击复制

化痰助运通络方治疗痰瘀互结型非酒精性脂肪肝肝纤维化临床研究
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
34
期数:
2021年05期
页码:
122-126
栏目:
衷中参西
出版日期:
2021-05-15

文章信息/Info

Title:
Clinical Study on Treating Non Alcoholic Fatty Liver Fibrosis of Phlegm and Blood Stasis Pattern by Resolving-phlegm Promoting-transportation Dredging-collateral Prescription
作者:
郭召平1, 苏琴1, 黄天生1,2
1.上海市嘉定区中医医院，上海 201800
2.上海中医药大学附属光华中西医结合医院
Author(s):
GUO Zhaoping1, SU Qin1, HUANG Tiansheng1,2
1.Shanghai City Jiading District TCM Hospital, Shanghai 201800, China
2.Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine
关键词:
非酒精性脂肪肝; 肝纤维化; 痰瘀互结; 化痰助运通络方
Keywords:
non alcoholic fatty liver; liver fibrosis; phlegm and blood stasis pattern; resolving-phlegm promoting-transportation dredging-collateral prescription
分类号:
R575
DOI:
10.12174/j.issn.2096-9600.2021.05.31
摘要:
目的观察化痰助运通络方治疗痰瘀互结型非酒精性脂肪肝肝纤维化的临床疗效。 方法将痰瘀互结型非酒精性脂肪肝肝纤维化患者77例随机分为治疗组39例，对照组38例，治疗组予化痰助运通络方治疗，对照组予易善复治疗，共治疗24周，观察治疗前后两组患者临床症状、肝功能、血脂、血清肝纤维化指标及Fibro-scan硬度值。 结果治疗组治疗后临床症状积分，γ-谷氨酰转肽酶（γ-glutamyl transpeptidase，γ-GT）、碱性磷酸酶（alkaline phosphatase，AKP）、透明质酸(hyaluronic acid，HA)、血清Ⅲ型前胶原氨端肽（procollagen Ⅲ，PcⅢ）、血清Ⅳ型胶原蛋白（type Ⅳ collagen，Ⅳ-C）、层黏连蛋白（laminin，LN）等与对照组比较差异均有统计学意义（P＜0.05）。两组患者谷丙转氨酶（alanine aminotransferase，ALT）、谷草转氨酶（aspartate aminotransferase，AST）、甘油三酯（triglyceride，TG）、总胆固醇（total cholesterol，TC）、高密度脂蛋白（high-density lipoprotein，HDL）、低密度脂蛋白（low densith lipoprotein，LDL）及Fibro-scan硬度值等比较差异均无统计学意义（P＞0.05）。总有效率治疗组为94.9%（37/39），高于对照组的81.6%（31/38），差异有统计学意义（P＜0.05）。 结论化痰助运通络方能改善非酒精性脂肪肝肝纤维化患者的临床症状、部分肝功能指标、血脂及血清肝纤维化等指标。
Abstract:
ObjectiveTo investigate clinical effects of resolving-phlegm promoting-transportation dredging-collateral prescription in the treatment of non alcoholic fatty liver fibrosis of phlegm and blood stasis pattern. MethodsA total of 77 patients were randomized into 39 cases of the treatment group and 38 cases of the control group, the treatment group was treated by resolving-phlegm promoting-transportation dredging-collateral prescription, and the control group took polyene phosphatidylcholine capsules, to observe clinical symptoms, liver function, blood lipid, serum markers of liver fibrosis and Fibro-scan stiffness between both groups before and after treating for 24 weeks. ResultsAfter treating, the difference was statistically significant when the treatment group was compared with the control group in clinical symptoms scores, γ-GT, AKP, PC Ⅲ, HA, Ⅳ-C, LN and others (P<0.05). The difference had no statistical meaning in ALT, AST, TG, TC, HDL, LDL, Fibro-scan stiffness between both groups (P>0.05). Total effective rate of the treatment group was 94.9%（37/39）, higher than 81.6%（13/38） of the control group, and the difference had statistical meaning between both groups (P<0.05). ConclusionResolving-phlegm promoting-transportation dredging-collateral prescription could improve clinical symptoms, partial indexes of liver function, blood lipid, serum hepatic fibrosis of the patients with non alcoholic fatty liver fibrosis of phlegm and blood stasis pattern.

相似文献/References:

[1]段尚勤.糖脂消合罗格列酮治疗2型糖尿病合并非酒精性脂肪肝疗效观察[J].西部中医药,2013,26(02):88.
　DUAN Shangqin.Clinical Observation on TangZhiXiao and Rosiglitazone Maleate in Treating Type 2 Diabetes Mellitus Complicated with Non Alcoholic Fatty Liver Disease[J].Western Journal of Traditional Chinese Medicine,2013,26(05):88.
[2]于立友,汪龙德△,张晶,等.化纤保肝方治疗气滞血瘀型肝纤维化的临床研究*[J].西部中医药,2013,26(10):84.
　YU Liyou,WANG Longde,ZHANG Jing,et al.Clinical Study on HuaQian BaoGan Prescription in the Treatment for Hepatic Fibrosis of Qi Staganation and Blood Stasis Pattern[J].Western Journal of Traditional Chinese Medicine,2013,26(05):84.
[3]刘成,杨宗国,陆云飞,等.消黄方对大鼠胆汁淤积性肝纤维化的干预作用*[J].西部中医药,2012,25(11):14.
　LIU Cheng,YANG Zong-guo,LU Yun-fei,et al.Therapeutic Effects of XiaoHuangFang on Cholestatic Liver Fibrosis in Rats[J].Western Journal of Traditional Chinese Medicine,2012,25(05):14.
[4]郭守强.苦参碱对肝纤维化大鼠转化生长因子β1表达的影响[J].西部中医药,2014,27(06):13.
　GUO Shouqiang.The Effects of Matrine on the Expressions of TGF-β1 of the Rats with Liver Fibrosis[J].Western Journal of Traditional Chinese Medicine,2014,27(05):13.
[5]闫雪华.恩替卡韦联合复方鳖甲软肝片治疗代偿期乙肝肝硬化疗效观察[J].西部中医药,2014,27(07):84.
　YAN Xuehua.Clinical Observation on Entecavir Combined with Compound BieJia RuanGan Tablets in Treating Decompensated Liver Cirrhosis of Hepatitis B[J].Western Journal of Traditional Chinese Medicine,2014,27(05):84.
[6]陈耀章,李根旺.冬虫夏草对心肝肾的保护作用研究[J].西部中医药,2016,29(04):127.
　CHEN Yaozhang,LI Genwang.Study on the Protective Effects of DongChong XiaCao to Heart, Liver and Kidney[J].Western Journal of Traditional Chinese Medicine,2016,29(05):127.
[7]张玉香,王一强,姜德民,等.清肝祛湿活血方对非酒精性脂肪肝大鼠Srebp-1c表达的影响[J].西部中医药,2016,29(07):19.
　ZHANG Yuxiang,WANG Yiqiang,JIANG Demin,et al.The Influence of QingGan QuShi HuoXue Prescription on the Expressions of Srebp-1c of the Rats with Non Alcoholic Fatty Liver Disease[J].Western Journal of Traditional Chinese Medicine,2016,29(05):19.
[8]余渊,程杰△.玉米须总皂苷对非酒精性脂肪肝大鼠SREBP1c和ACCα的影响[J].西部中医药,2018,31(09):21.
　YU Yuan,CHENG Jie.Effects of Total Saponins Extracted from Stigmata Maydis on SREPB1c and ACCα of the Rats with Nonalcoholic Fatty Liver Disease[J].Western Journal of Traditional Chinese Medicine,2018,31(05):21.
[9]张玉玲,闫雪华△,谢青.中药联合抗病毒药物治疗HBV所致肝纤维化的研究进展[J].西部中医药,2019,32(06):149.
　ZHANG Yuling,YAN Xuehua,XIE Qing.The Progress of Herbs Joined with Antiviral Drugs in the Treatment for HBV - induced Hepatic Fibrosis[J].Western Journal of Traditional Chinese Medicine,2019,32(05):149.
[10]程亚伟,王婷,王珊,等.中医湿证与非酒精性脂肪肝程度关联性分析[J].西部中医药,2020,33(05):102.[doi:10.12174/j.issn.1004-6852.2020.05.29]
　CHENG Yawei,WANG Ting,WANG Shan,et al.The Correlation Analysis between TCM Dampness Syndrome and the Degrees of NAFLD[J].Western Journal of Traditional Chinese Medicine,2020,33(05):102.[doi:10.12174/j.issn.1004-6852.2020.05.29]

备注/Memo

备注/Memo:
郭召平（1982—），男，硕士学位，主治医师。研究方向：消化系统疾病的中医药治疗。上海市嘉定区卫生和计划生育委员会中医药科研课题（2015-KY-ZYY-02）。
更新日期/Last Update: 2021-05-15